|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
WO1989008114A1
(en)
|
1988-02-25 |
1989-09-08 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
AU658370B2
(en)
|
1990-07-13 |
1995-04-13 |
General Hospital Corporation, The |
CD53 cell surface antigen and use thereof
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
AU6123894A
(en)
|
1993-01-29 |
1994-08-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
|
|
GB9424449D0
(en)
|
1994-12-02 |
1995-01-18 |
Wellcome Found |
Antibodies
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
JP4233608B2
(ja)
|
1996-10-15 |
2009-03-04 |
塩野義製薬株式会社 |
自己抗体測定方法
|
|
ES2191827T3
(es)
|
1996-10-17 |
2003-09-16 |
Immunomedics Inc |
Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
|
|
WO2000006194A2
(en)
|
1997-02-05 |
2000-02-10 |
Biotransplant, Inc. |
Depletion of cells responsible for antibody-mediated graft rejection
|
|
ATE302217T1
(de)
|
1997-05-02 |
2005-09-15 |
Us Gov Health & Human Serv |
Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
|
|
AU770718B2
(en)
*
|
1998-06-05 |
2004-02-26 |
Mayo Foundation For Medical Education And Research |
Use of genetically engineered antibodies to CD38 to treat multiple myeloma
|
|
US7223397B1
(en)
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
PT1256576E
(pt)
|
2000-02-15 |
2005-09-30 |
Astellas Pharma Inc |
Derivados de imidazolio fundidos
|
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
|
WO2001097844A1
(en)
|
2000-06-22 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
EP1174440A1
(en)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
|
|
US20070042436A1
(en)
|
2000-10-17 |
2007-02-22 |
Lund Frances E |
CD38 modulated chemotaxis
|
|
US6955884B2
(en)
|
2000-10-17 |
2005-10-18 |
Trudeau Institute, Inc. |
Methods for identifying compounds that inhibit CD38 activity
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
US20040166490A1
(en)
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
ES2295639T3
(es)
|
2002-06-13 |
2008-04-16 |
Crucell Holland B.V. |
Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
|
|
EP2330213A1
(en)
|
2003-03-05 |
2011-06-08 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
KR101015034B1
(ko)
|
2003-04-15 |
2011-02-16 |
아스텔라스세이야쿠 가부시키가이샤 |
브롬화물 및 이의 결정
|
|
RS20150135A1
(sr)
|
2003-05-30 |
2015-08-31 |
Genentech Inc. |
Tretman sa anti-vegf antitelima
|
|
JP4794301B2
(ja)
|
2003-06-11 |
2011-10-19 |
中外製薬株式会社 |
抗体の製造方法
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1689435A4
(en)
|
2003-10-22 |
2007-10-03 |
Univ Rochester |
ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
|
|
PT1684805E
(pt)
|
2003-11-04 |
2010-10-26 |
Novartis Vaccines & Diagnostic |
Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
|
|
JP4712724B2
(ja)
|
2003-12-23 |
2011-06-29 |
クルセル ホランド ベー ヴェー |
ＣＤ１ａに対するヒト結合分子
|
|
MXPA06008700A
(es)
|
2004-02-06 |
2007-01-19 |
Morphosys Ag |
Anticuerpos anti-cd38 humanos y usos para los mismos.
|
|
EP2915820A1
(en)
|
2004-02-06 |
2015-09-09 |
MorphoSys AG |
Anti-CD38 human antibodies and uses therefor
|
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
CN101287764B
(zh)
|
2005-10-12 |
2013-11-13 |
莫佛塞斯公司 |
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
|
|
MX2008007140A
(es)
|
2005-12-09 |
2009-03-04 |
Seattle Genetics Inc |
Metodos para utilizar agentes de union a cd40.
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
JP2009545601A
(ja)
|
2006-08-02 |
2009-12-24 |
サネシス ファーマシューティカルズ， インコーポレイテッド |
（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
|
|
WO2008073160A2
(en)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
PL2081595T3
(pl)
|
2006-09-26 |
2019-11-29 |
Genmab As |
Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
|
CA2681743A1
(en)
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
|
EP2626372B1
(en)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
KR101540823B1
(ko)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
|
AU2008260445A1
(en)
|
2007-06-01 |
2008-12-11 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
|
RU2491095C2
(ru)
|
2007-11-09 |
2013-08-27 |
Новартис Аг |
Применения анти-cd40-антител
|
|
EP2237798A2
(en)
|
2007-12-12 |
2010-10-13 |
Imperial Innovations Limited |
Methods
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
US8013125B2
(en)
|
2008-03-03 |
2011-09-06 |
Dyax Corp. |
Metalloproteinase 9 and metalloproteinase 2 binding proteins
|
|
CN101970650B
(zh)
|
2008-03-06 |
2017-07-25 |
哈洛齐梅公司 |
可溶性透明质酸酶的大规模生产
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
BRPI0909227B8
(pt)
|
2008-03-25 |
2021-05-25 |
Roche Glycart Ag |
uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
|
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
HUE043326T2
(hu)
|
2008-11-07 |
2019-08-28 |
Amgen Res Munich Gmbh |
Akut limfoblasztos leukémia kezelése
|
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
SMT202000092T1
(it)
|
2009-05-14 |
2020-05-08 |
Ambit Biosciences Corp |
Formulazione essiccata a spruzzo o liofilizzata di ac220
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
PT2477603E
(pt)
|
2009-09-17 |
2016-06-16 |
Baxalta Inc |
Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
|
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
|
SG184355A1
(en)
|
2010-03-01 |
2012-11-29 |
Progenics Pharm Inc |
Concentrated protein formulations and uses thereof
|
|
US20110210017A1
(en)
|
2010-03-01 |
2011-09-01 |
Lai Rebecca Y |
Fabrication of electrochemical biosensors via click chemistry
|
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
|
WO2011121588A1
(en)
|
2010-03-29 |
2011-10-06 |
Ben Gurion University Of The Negev Research And Development Authority |
Method and system for detecting and monitoring hematological cancer
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
EP2420253A1
(en)
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
|
|
US8877899B2
(en)
|
2010-09-27 |
2014-11-04 |
Morphosys Ag |
Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
JOP20210044A1
(ar)
*
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
CL2013001944A1
(es)
|
2010-12-30 |
2014-09-12 |
Takeda Pharmaceutical |
Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
|
|
KR101606250B1
(ko)
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
|
US20140051662A1
(en)
|
2011-04-08 |
2014-02-20 |
Ab Science |
Treatment of multiple myeloma with masitinib
|
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
EP2747571A4
(en)
|
2011-08-24 |
2015-05-27 |
David Kerr |
COMBINED COMBINED CHEMOTHERAPY
|
|
EP2561868A1
(en)
|
2011-08-24 |
2013-02-27 |
Anton Bernhard Van Oosten |
Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
WO2013083140A1
(en)
|
2011-12-07 |
2013-06-13 |
N.V. Nutricia |
Beta-lactoglobulin peptides for treating cow's milk protein allergy
|
|
SG11201403714TA
(en)
|
2011-12-30 |
2014-07-30 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
FR2987254B1
(fr)
*
|
2012-02-24 |
2015-06-12 |
Helgoual Ch Guy L |
Dispositif endoscopique destine notamment a un usage medical.
|
|
KR20160105535A
(ko)
|
2012-03-07 |
2016-09-06 |
카딜라 핼쓰캐어 리미티드 |
TNF-α 항체의 약제학적 제형
|
|
EP2833905B1
(en)
|
2012-04-04 |
2018-05-02 |
Halozyme, Inc. |
Combination therapy with hyaluronidase and a tumor-targeted taxane
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
HRP20171964T1
(hr)
|
2012-09-25 |
2018-02-23 |
Morphosys Ag |
Kombinacije i njihova upotreba
|
|
US9486547B2
(en)
|
2012-11-05 |
2016-11-08 |
Morphosys Ag |
Radiolabelled antibody and uses thereof
|
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
|
WO2014100740A1
(en)
|
2012-12-21 |
2014-06-26 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
|
WO2014142220A1
(ja)
|
2013-03-13 |
2014-09-18 |
アステラス製薬株式会社 |
抗腫瘍剤
|
|
US20140271644A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Combination/adjuvant therapy for wt-1-positive disease
|
|
CA2909952C
(en)
|
2013-04-29 |
2021-10-12 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
US20140356318A1
(en)
|
2013-05-28 |
2014-12-04 |
Israel Barken |
Adoptive cell therapy with specific regulatory lymphocytes
|
|
EP3021866A4
(en)
|
2013-07-15 |
2017-02-22 |
The Board of Trustees of the Leland Stanford Junior University |
Medical uses of cd38 agonists
|
|
MX373301B
(es)
*
|
2013-10-31 |
2020-04-24 |
Sanofi Sa |
Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
|
|
JP2016536361A
(ja)
|
2013-11-06 |
2016-11-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
|
|
DK3105317T3
(en)
|
2014-02-14 |
2019-01-14 |
Cellectis |
Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
EP3154581B1
(en)
|
2014-06-16 |
2019-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
|
|
WO2015195555A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
WO2016040294A2
(en)
|
2014-09-09 |
2016-03-17 |
Janssen Biotech, Inc. |
Combination therapies with anti-cd38 antibodies
|
|
PE20171094A1
(es)
|
2014-12-04 |
2017-08-07 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
|
|
EP3229845B1
(en)
|
2014-12-10 |
2020-05-27 |
University of Southern California |
Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
|
|
MA41555A
(fr)
|
2015-02-17 |
2017-12-26 |
Millennium Pharm Inc |
Polythérapie pour le traitement du cancer
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
CN107708734B
(zh)
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
|
EP3313441B1
(en)
|
2015-06-24 |
2024-02-21 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
CA2990705A1
(en)
|
2015-06-29 |
2017-01-05 |
Abraxis Bioscience, Llc |
Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
US20170121417A1
(en)
*
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
|
JP7027321B2
(ja)
|
2015-11-03 |
2022-03-01 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体の皮下製剤及びその使用
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
US20180117150A1
(en)
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
|
CN110913911A
(zh)
|
2017-05-18 |
2020-03-24 |
特沙诺有限公司 |
用于治疗癌症的组合疗法
|
|
US11618787B2
(en)
|
2017-10-31 |
2023-04-04 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
CA3095086A1
(en)
|
2018-03-28 |
2019-10-03 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-cd38 antibodies
|
|
US20190298827A1
(en)
|
2018-04-03 |
2019-10-03 |
Janssen Biotech, Inc. |
Methods of Treating Multiple Myeloma
|
|
WO2019220368A1
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
MA53920A
(fr)
|
2018-10-17 |
2021-09-15 |
Janssen Biotech Inc |
Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
|
|
CN113015805B
(zh)
|
2018-11-13 |
2024-12-03 |
詹森生物科技公司 |
抗cd38抗体产生期间的痕量金属的控制
|
|
WO2020170211A1
(en)
|
2019-02-22 |
2020-08-27 |
Janssen Biotech, Inc. |
Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone
|
|
WO2020194243A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
|
|
US20200308297A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
|
|
US20200316197A1
(en)
|
2019-03-28 |
2020-10-08 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
|
|
US20200308296A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
|
|
WO2020194245A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone
|
|
US20200405854A1
(en)
|
2019-04-19 |
2020-12-31 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
US20200392242A1
(en)
|
2019-04-19 |
2020-12-17 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
US20200397896A1
(en)
|
2019-04-19 |
2020-12-24 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
|
WO2020243911A1
(zh)
|
2019-06-04 |
2020-12-10 |
上海科技大学 |
Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
|
|
US20220275101A1
(en)
*
|
2021-02-09 |
2022-09-01 |
Janssen Biotech, Inc. |
Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis
|
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|